Lee, Kyung-Tae Lee, Dong-Gi Choi, Ji Won Park, Jong-Hyun Park, Ki Duk Lee, Jong-Seung Bahn, Yong-Sun 2024-01-19T12:30:35Z 2024-01-19T12:30:35Z 2022-04-03 2022-04 1225-8873 https://pubs.kist.re.kr/handle/201004/115481 Systemic candidiasis, which is mainly caused by Candida albicans, is a serious acute fungal infection in the clinical setting. In a previous study, we reported that compound 22h (designated as AB-22 in this study), a vinyl sulfate compound, is a fast-acting fungicidal agent against a broad spectrum of fungal pathogens. In this study, we aimed to further analyze the in vitro and in vivo efficacy of AB-22 against filamentation, biofilm formation, and virulence of C. albicans. Under in vitro hyphal growth-inducing condition, AB-22 effectively inhibited germ tube formation and hyphal growth, which are required for the initiation of biofilm formation. Indeed, AB-22 significantly suppressed C. albicans biofilm formation in a dose-dependent manner. Moreover, AB-22 treatment inhibited the normal induction of ALS3, HWP1, and ECE1, which are all required for hyphal transition in C. albicans. Furthermore, AB-22 treatment increased the survival of mice systemically infected with C. albicans. In conclusion, in addition to its fungicidal activity, AB-22 inhibits filamentation and biofilm formation in C. albicans, which could collectively contribute to its potent in vivo efficacy against systemic candidiasis. English MICROBIOLOGICAL SOCIETY KOREA The novel antifungal agent AB-22 displays in vitro activity against hyphal growth and biofilm formation in Candida albicans and potency for treating systemic candidiasis Article 10.1007/s12275-022-2016-0 1 JOURNAL OF MICROBIOLOGY, v.60, no.4, pp.438 - 443 JOURNAL OF MICROBIOLOGY 60 4 438 443 N scie scopus kci ART002823526 000768616700002 2-s2.0-85126212238 Microbiology Microbiology Article; Early Access INVASIVE CANDIDIASIS RESISTANCE systemic candidiasis biofilm antifungal drug efficacy